# Genoskin

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/genoskin

- Headquarters: Salem, US
- Website: www.genoskin.com
- Total disclosed funding: $5.4M
- Latest round: Series A (Sep 16, 2025)
- Investors on record: 3

## About

Genoskin Inc. is a US-based company that provides innovative ex vivo human skin models for research and drug development, catering to various sectors including therapeutics, vaccines, and cosmetics.Genoskin Inc. specializes in the creation of ex vivo human skin models derived from donated human skin, supporting research across multiple industries. Founded in 2011 in Salem, US, the company has secured significant funding, including a recent Series A round where it raised USD 5.40 mn led by OCCTE. Genoskin has completed two funding rounds to date, with the most recent deal announced on September 16, 2025.Genoskin develops and provides innovative ex vivo human skin models such as NativeSkin®, HypoSkin®, and InflammaSkin®. These models facilitate testing in sectors like therapeutics, vaccines, and cosmetics, maintaining tissue viability for up to seven days post-surgery, thereby supplying authentic data relevant for various research applications.Genoskin's revenue is primarily generated through direct sales of its proprietary skin models and associated services for B2B clients in the pharmaceutical and cosmetic sectors. Clients engage in customized research projects involving model purchases and analysis services, reflecting the high value of the insights provided.In September 2025, Genoskin Inc. raised USD 3.30 mn in venture debt funding as part of a larger USD 8.70 mn Series A round. This funding will be used to support the company's growth, including hiring additional staff and expanding its commercial presence in major global markets.

## Funding rounds

- Series A, Sep 16, 2025, $5.4M — Grand Sud Ouest Capital, OCCTE, CAPTECH Sante

## Investors

- Grand Sud Ouest Capital (https://capitalatlas.ai/funds/grand-sud-ouest-capital) — Series A
- OCCTE — Series A
- CAPTECH Sante — Series A